 |
236 Diseases |  |
42 Trials |
|
42 Trials |  |
3908 News |  |
| «12...4567891011121314...4849» |
- ||| Kadcyla (ado-trastuzumab emtansine) / Roche
Trial completion date, Metastases: BO29919: Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 11, 2023
P3, N=351, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Oct 2022 --> Jan 2023
- | Votrient (pazopanib) / Novartis, Sutent (sunitinib) / Pfizer
Biomarker, Journal, Tumor microenvironment: Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer. (Pubmed Central) - Jan 10, 2023
The high-risk group possessed a worse immune infiltration and poor survival, with higher tumor mutations and lapatinib and paclitaxel that may be better choices in this group. In conclusion, we developed an original seven-PRlncRNA risk signature to predict prognosis, TME infiltration, tumor mutation, and therapeutic options for PC patients.
- || Review, Journal: Smart Polymeric Micelles for Anticancer Hydrophobic Drugs. (Pubmed Central) - Jan 9, 2023
For this reason, we evaluate the influence of the synthesis methods and the physicochemical properties of these systems that subsequently allow an effective encapsulation and release of the drug. On the other hand, we demonstrate how computational chemistry will enable us to guide and optimize the design of these micelles to carry out better experimental work.
- | Herceptin (trastuzumab) / Roche
Journal, Tumor-infiltrating lymphocyte: Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. (Pubmed Central) - Jan 6, 2023
Results of this study suggest that multiple B-cell-related signatures were more strongly associated with pCR and EFS than TILs, which largely represent T cells. When both TILs and gene expression are available, the prognostic value of immune-related signatures appears to be superior.
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
Retrospective data, Review, Journal, Metastases: Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review. (Pubmed Central) - Jan 6, 2023
When both TILs and gene expression are available, the prognostic value of immune-related signatures appears to be superior. The efficacy of pyrotinib combined with chemotherapy is superior to lapatinib combined with chemotherapy but has more safety risks.
- | Sutent (sunitinib) / Pfizer
Journal, IO biomarker: Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma. (Pubmed Central) - Jan 4, 2023
Furthermore, AL133243.2 is a promising marker for predicting immunotherapy response in HCC patients. This data may facilitate further exploration of more effective immunotherapy strategies for HCC.
- | lapatinib / Generic mfg., fulvestrant / Generic mfg.
Journal: PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies. (Pubmed Central) - Jan 4, 2023
This data may facilitate further exploration of more effective immunotherapy strategies for HCC. Our data provide in vivo evidence that PAQR8 plays a functional role in cancer, implicate PAQR8, cAMP, and ceramide metabolism in breast cancer recurrence, and identify a novel mechanism that may commonly contribute to the acquisition of treatment resistance in breast cancer patients.
- ||| lapatinib / Generic mfg., Tukysa (tucatinib) / Seagen, Herceptin (trastuzumab) / Roche
Clinical, European regulatory, Combination therapy, Metastases: The TKIs lapatinib and tucatinib are EMA-approved for the treatment of patients with hormone receptor-negative/HER2-positive metastatic BC, which has progressed on prior trastuzumab-based therapy in combination with chemotherapy. (Twitter) - Jan 2, 2023
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
Review, Journal: Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer. (Pubmed Central) - Dec 30, 2022
The antibody-drug conjugates adotrastuzumab, emtansine, famtrastuzumab, and deruxtecan, as well as the anti-HER2 monoclonal antibody pertuzumab are used in both early-stage and metastatic situations, either alone or in conjunction with chemotherapy and other HER2-targeting therapies...Anti-HER2 ligands can be used in various nano formulations to target HER2 receptors. Here we will discuss, targeted TKIs in patients with HER2+ BC, clinical studies of HER2+ targeted TKIs, mechanisms of resistance to HER2-directed therapies with new implications of TKIs in HER2+ MBC (metastatic breast cancer) and anti-HER2 ligand in various nano formulations to target HER2 receptors.
- | lapatinib / Generic mfg.
Journal: Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment. (Pubmed Central) - Dec 24, 2022
Moreover, the cytotoxicity studies confirmed that the blank chitosan decorated LBNP is not toxic to the cells with the tested concentrations, which correspond to LAPA concentrations from 1 to 10 µM, at different incubation times up to 96 h. Furthermore, siCtrl.-LAPA_LBNP had a more cytotoxic effect than Lapatinib salt, while siSurvivin-LAPA_LBNP had a significant synergistic cytotoxic effect compared to siCtrl.-LAPA_LBNP. All these findings suggested that the developed modified LBNP could potentiate anti-Survivin siRNA and LAPA anti-cancer activity.
- | lapatinib / Generic mfg.
Journal: Evaluation of Lapatinib-Loaded Microfibers Prepared by Centrifugal Spinning. (Pubmed Central) - Dec 24, 2022
Meanwhile the crystalline Lap formed a 30-40 μg/mL (6-8%) solution in 5 min, maintaining that concentration. We conclude that centrifugal spinning can be an effective and easy method to produce ASDs.
- | Herceptin (trastuzumab) / Roche, Bystolic (nebivolol) / Menarini, AbbVie
Journal: Screening of GPCR drugs for repurposing in breast cancer. (Pubmed Central) - Dec 24, 2022
Analysis of the Surveillance, Epidemiology and End Results (SEER)-Medicare dataset found numerically but not statistically significant reduced risk of all-cause mortality in the nebivolol group. In-depth future analyses, including detailed in vivo studies and real-world data analysis with more patients, are needed to further investigate the potential of nebivolol as a repurposed therapy for BC.
- | lapatinib / Generic mfg.
Journal: Vesicle-mediated transport-related genes are prognostic predictors and are associated with tumor immunity in lung adenocarcinoma. (Pubmed Central) - Dec 17, 2022
High-risk group patients were more sensitive to several chemotherapeutic drugs and Lapatinib...The risk model was associated with immune infiltration levels. These five hub genes are potential targets for immune therapy combined with chemotherapy in LUAD.
- | lapatinib / Generic mfg., gefitinib / Generic mfg., sorafenib / Generic mfg.
Journal: Inhibitory effects of Thai herbal extracts on the cytochrome P450 3A-mediated the metabolism of gefitinib, lapatinib and sorafenib. (Pubmed Central) - Dec 16, 2022
In addition, kinetic analysis of the ability of Curcuma zedoaria extract to inhibit CYP3A-mediated metabolism of anticancer drugs was best described by the noncompetitive and competitive inhibition models with K values of 20.08 and 11.55 μg/mL for the metabolism of gefitinib and sorafenib, respectively. The present study demonstrated that there were potential pharmacokinetic interactions between tyrosine kinase inhibitors and herbal extracts.
- || veliparib (ABT-888) / AbbVie
Trial completion date, Trial primary completion date: Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer (clinicaltrials.gov) - Dec 14, 2022
P=N/A, N=23, Active, not recruiting, Sponsor: University of Alabama at Birmingham
The present study demonstrated that there were potential pharmacokinetic interactions between tyrosine kinase inhibitors and herbal extracts. Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
- Tukysa (tucatinib) / Seagen, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
A systematic review to assess the efficacy of HER2-targeted treatment regimens in HER2-positive metastatic colorectal cancer (mCRC). (On Demand | Level 1, West Hall; Poster Board No. J6) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_829;
Long term data are needed to define clinical efficacious based on survival endpoints. >
- || Herceptin (trastuzumab) / Roche
Retrospective data, Review, Journal: Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis. (Pubmed Central) - Dec 12, 2022
The efficacy of trastuzumab combined with lapatinib therapy is superior to standard trastuzumab therapy alone; however, it has more non-cardiac grade III/IV toxicities. Moreover, the efficacy of lapatinib therapy is inferior to that of standard trastuzumab therapy alone.
- | Zelboraf (vemurafenib) / Roche, Visudyne (verteporfin) / Novartis
Journal: Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors. (Pubmed Central) - Dec 9, 2022
YAP governs adaptive resistance to RAF kinase inhibitors and induces a gene expression program in BRAF-mutant cells encompassing effectors in the NRG1 signaling pathway, which play a central role in the insensitivity to MAPK inhibitors in a lineage-dependent manner. HIPPO pathway inactivation serves as a lineage-dependent rheostat controlling the magnitude of the adaptive relief of feedback responses to MAPK inhibitors in BRAF- cancers.
- | lapatinib / Generic mfg.
Journal: Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition. (Pubmed Central) - Dec 6, 2022
Moreover, ERK5 knockdown restored the anti-tumor activity of the anti-HER2 agent lapatinib in human breast cancer xenografts. Taken together, these findings support the therapeutic potential of ERK5 inhibitors to improve the clinical benefit that patients receive from targeted HER2 therapies.
- | Preclinical, Journal, IO biomarker: Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies. (Pubmed Central) - Dec 3, 2022
MTT assay, gene expression analysis (BAX, BCL-2, and β-catenin), apoptosis analysis, TEM, cell cycle assay, ELISA, and cell migration assays were conducted to perform the cell death analysis of lung cancer and breast cancer, compared to the marketed product. The MTT assay exhibited 80% cell death for 75 µM and 100µM; however, flow cytometry analysis with the IC value demonstrated that the selected compound induced higher apoptosis in MCF-7 (30.8%) than in A549.
- | Votrient (pazopanib) / Novartis, saracatinib (AZD0530) / AstraZeneca
Journal, Gene Signature: Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer. (Pubmed Central) - Dec 2, 2022
The MTT assay exhibited 80% cell death for 75 µM and 100µM; however, flow cytometry analysis with the IC value demonstrated that the selected compound induced higher apoptosis in MCF-7 (30.8%) than in A549. This study revealed the effects of CRLs on BCa and further established CRLs model, which can be used in clinic for predicting prognosis, immunological response and treatment sensitivity inpatient with BCa.
- ||| lapatinib / Generic mfg.
Clinical: We would use Lapatinib combination in such a patient. control arm could have been better? (Twitter) - Dec 1, 2022
- || Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
PK/PD data, Journal: Oncoinformatic screening of the gene clusters involved in the HER2-positive breast cancer formation along with the in silico pharmacodynamic profiling of selective long-chain omega-3 fatty acids as the metastatic antagonists. (Pubmed Central) - Nov 30, 2022
Finally, potential drug targets for EPA and DHA in breast cancer were constructed to determine the drug-protein interactions (DPI) at metabolic stages. Considering the values resulting from the combinational models of the oncoinformatic, pharmacodynamic, and metabolic parameters, long-chain omega-3 fatty acids like EPA and DHA can be considered as potential-targeted therapeutics for HER2-positive breast cancer treatment.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
First results from the randomized phase III DETECT III trial - efficacy of lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells (Helsinki 1) - Nov 30, 2022 - Abstract #DKK2022DKK_918;
P=N/A
JADE will, for the first time, present real-world data on pts_x000D_ and tumor characteristics, treatment and outcomes of pts with liver and_x000D_ biliary tract cancer across all health care sectors in Germany. In the future,_x000D_ JADE will shed light on the treatment landscape in real-world and will_x000D_ help to identify unmet medical needs for future clinical research.
- | lapatinib / Generic mfg., everolimus / Generic mfg., erlotinib / Generic mfg.
Journal: TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors. (Pubmed Central) - Nov 27, 2022
None of the other drugs were able to maintain comparable effects upon removal. Although we observed slightly additive effects when the TNBC cells were treated with FC101 and the two EGFR inhibitors, those effects were not truly synergistic in the manner displayed with everolimus.
- | lapatinib / Generic mfg.
Journal, Combination therapy, PARP Biomarker, IO biomarker: Prostate Cancer Cells Are Sensitive to Lysosomotropic Agent Siramesine through Generation Reactive Oxygen Species and in Combination with Tyrosine Kinase Inhibitors. (Pubmed Central) - Nov 27, 2022
Although we observed slightly additive effects when the TNBC cells were treated with FC101 and the two EGFR inhibitors, those effects were not truly synergistic in the manner displayed with everolimus. This suggests that lysomotropic agents such as siramesine in combination with tyrosine kinase inhibitors induces cell death mediated by ROS and could be an effective treatment strategy in advanced prostate cancer.
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
Retrospective data, Review, Journal: Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis. (Pubmed Central) - Nov 27, 2022
Though our meta-analysis should be interpreted with caution due to the heterogeneity of included studies and a related serious risk of bias, this review provides a comprehensive overview of all currently available systemic treatment options. T-Dxd and TTC that appear to constitute the most effective systemic therapy in patients with HER2+ mBC and BM, while pyrotinib might be an option in Asian patients.
- Herceptin (trastuzumab) / Roche
Gene expression profile at week 2 of neoadjuvant therapy course predicts outcome in HER2-positive breast cancer patients: an explorative analysis from NeoALTTO (Exhibition Hall) - Nov 23, 2022 - Abstract #EBCC2022EBCC_492;
Biomarkers of early T-cell and monocyte-macrophage activation, as well as HER2 downregulation hold the potential to reliably identify patients likely to achieve a pCR and a favorable prognosis. New effective treatments need to be explored for cases lacking an early GEP response.
- | Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
Journal, HEOR: Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis. (Pubmed Central) - Nov 22, 2022
New effective treatments need to be explored for cases lacking an early GEP response. Ner+Cap was likely to be a cost-effective regimen as the third-line therapy for women with HER2-positive MBC at the willingness-to-pay threshold of $37 653.0/QALY in China.
- | Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
Journal: Neratinib (Nerlynx) for metastatic HER2-positive breast cancer. (Pubmed Central) - Nov 18, 2022
Ner+Cap was likely to be a cost-effective regimen as the third-line therapy for women with HER2-positive MBC at the willingness-to-pay threshold of $37 653.0/QALY in China. No abstract available
- | lapatinib / Generic mfg., paclitaxel / Generic mfg.
Journal, IO biomarker: A new acidic microenvironment related lncRNA signature predicts the prognosis of liver cancer patients. (Pubmed Central) - Nov 18, 2022
Finally, the expression levels of the seven lncRNAs comprising the signature were tested by qRT-PCR. A basis for the mechanism of AME-associated lncRNAs in LC is provided by the prediction signature, which also offers clinical therapeutic recommendations for LC individuals.
- ||| Journal, Adverse events: Identifying new drugs associated with pulmonary arterial hypertension: a WHO pharmacovigilance database disproportionality analysis. (Pubmed Central) - Nov 18, 2022
Such signals represent plausible adverse drug reactions considering the knowledge of iatrogenic PAH, the drugs' biological and pharmacological activity and the characteristics of the reported case. Although confirmatory studies need to be performed, the signals identified may help clinicians envisage an iatrogenic aetiology when faced with a patient who develops PAH.
- | Beleodaq (belinostat) / Aurobindo, navitoclax (ABT 263) / AbbVie
Journal, IO biomarker: Diagnostic, prognostic, and immunological roles of CD177 in cervical cancer. (Pubmed Central) - Nov 16, 2022
Although confirmatory studies need to be performed, the signals identified may help clinicians envisage an iatrogenic aetiology when faced with a patient who develops PAH. These findings may shed light on the vital role of CD177 in cervical cancer diagnosis, prognosis, and immunological functions, and it may be a promising predictor and potential factor for cervical cancer patients.
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Herceptin (trastuzumab) / Roche
Journal: The Prognostic and Therapeutic Implications of the Chemoresistance Gene BIRC5 in Triple-Negative Breast Cancer. (Pubmed Central) - Nov 16, 2022
Meanwhile, several in vitro studies show that flavonoids were highly effective in inhibiting BIRC5 in genetically diverse TNBC cells. Therefore, flavonoids would be a promising strategy for preventing and treating TNBC patients with the BIRC5 molecule.
- | lapatinib / Generic mfg.
Journal: Screening, Docking, and Molecular Dynamics Study of Natural Compounds as an Anti-HER2 for the Management of Breast Cancer. (Pubmed Central) - Nov 16, 2022
The amino acid residues Leu726, Val734, Ala751, Lys753, Thr798, Gly804, Arg849, Leu852, Thr862, and Asp863 were found in common interaction as compared to the control compound Lapatinib...Several drug-likeness rules like Lipinski, Ghose, Veber, Egan, and Muegge were checked and found to be positive for these rules. Based on these calculations and different parameters, these top two selected natural compounds can be used as potential candidates for anti-HER2 for the management of BC.
- | Herceptin (trastuzumab) / Roche
Journal: Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study. (Pubmed Central) - Nov 15, 2022
P3
Based on these calculations and different parameters, these top two selected natural compounds can be used as potential candidates for anti-HER2 for the management of BC. With most patients treated with anthracycline-based regimens, ALTTO shows that patients with small tumours treated with trastuzumab and concomitant chemotherapy have excellent long-term outcomes, similar to those of the APT trial.
- ||| oxaliplatin / Generic mfg., lapatinib / Generic mfg., capecitabine / Generic mfg.
Trial completion date, Metastases: LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib (clinicaltrials.gov) - Nov 14, 2022
P3, N=545, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
With most patients treated with anthracycline-based regimens, ALTTO shows that patients with small tumours treated with trastuzumab and concomitant chemotherapy have excellent long-term outcomes, similar to those of the APT trial. Trial completion date: Dec 2022 --> Jun 2023
- ||| lapatinib / Generic mfg., Herceptin (trastuzumab) / Roche
Clinical: Any prospective evidence in BTC is great. The first useful data with Trastuzumab in HER2 positive BTC with actually good outcomes. Way to go. Would be interested if Lapatinib, Td would also become applicable. @Amolpatel_dr @VirajLavingia (Twitter) - Nov 12, 2022
- | lapatinib / Generic mfg.
Journal: EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts. (Pubmed Central) - Nov 10, 2022
Inhibition of the EGFR pathway with lapatinib suppresses matrix metalloproteinases synthesis. Our results suggest EGFR pathway inhibition may be a promising option to prevent joint destruction in the treatment of rheumatoid arthritis.
- | Sutent (sunitinib) / Pfizer, saracatinib (AZD0530) / AstraZeneca
Journal: Metal-dependent programmed cell death-related lncRNA prognostic signatures and natural drug sensitivity prediction for gastric cancer. (Pubmed Central) - Nov 8, 2022
Our 12 metal-dependent PCD-related lncRNA prognostic signature model may improve the OS prediction for gastric cancer. The antitumor drug sensitivity analysis results may also be helpful for individualized chemotherapy regimen design.
- | Herceptin (trastuzumab) / Roche
Journal: ALKBH5-mediated m6A demethylation of GLUT4 mRNA promotes glycolysis and resistance to HER2-targeted therapy in breast cancer. (Pubmed Central) - Nov 4, 2022
Moreover, suppression of GLUT4 via genetic knockdown or pharmacological targeting with a specific inhibitor profoundly restored the response of resistant breast cancer cells to trastuzumab and lapatinib both in vitro and in vivo. In conclusion, ALKBH5-mediated m6A demethylation of GLUT4 mRNA promotes resistance to HER2-targeted therapy, and targeting the ALKBH5/GLUT4 axis has therapeutic potential for treating breast cancer patients refractory to HER2-targeted therapies.
- |||| lapatinib / Generic mfg., Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical: Selected by EIC @NamBuiMD, this #CaseOfTheWeek presents an HER2+ #MBC patient & the dramatic response of HER2 triple blockade using trastuzumab, pertuzumab, and lapatinib w/o cytotoxic agents. #OncTwitter #CPCcasereports #MedTwitter https://t.co/GXqnBW9nJZ (Twitter) - Nov 1, 2022
- || Irene (pyrotinib) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
P2 data, Journal: Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial. (Pubmed Central) - Nov 1, 2022
In conclusion, ALKBH5-mediated m6A demethylation of GLUT4 mRNA promotes resistance to HER2-targeted therapy, and targeting the ALKBH5/GLUT4 axis has therapeutic potential for treating breast cancer patients refractory to HER2-targeted therapies. Pyrotinib plus trastuzumab and chemotherapy offered a promising option with manageable safety profile for heavily pre-treated HER2-positive MBC, especially for those without liver or/and lung metastases.
- ARX788 / Ambrx, Kadcyla (ado-trastuzumab emtansine) / Roche
ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+ metastatic breast cancer previously treated with T-DM1 (Stars at Night Ballrooms 3&4) - Oct 28, 2022 - Abstract #SABCS2022SABCS_2014;
P2
In this small cohort of patients previously treated with T-DM1, ARX788 had a manageable AE profile and demonstrated promising clinical activity (confirmed ORR 57%; DCR 100%). ACE-Breast-03 Spider Plot for patients with mBC who were previously treated with T-DM1 ARX788 demonstrated promising clinical activity in patients previously treated with T-DM1.
- Herceptin (trastuzumab) / Roche
Prognostic implications of PIK3CA mutation by hormone receptor status and intrinsic subtype in early stage HER2-positive breast cancer: a correlative analysis from CALGB 40601 (Stars at Night Ballrooms 3&4) - Oct 28, 2022 - Abstract #SABCS2022SABCS_2009;
Conclusion In our study, the presence of PIK3CA mutation was significantly associated with lower pCR rates in patients treated with chemotherapy plus trastuzumab. Moreover, in uni- and multivariable Cox models, PIK3CA mutations were associated with worse long-term survival, which appeared to be driven by HR-positive and luminal HER2-positive breast tumors.
- || Herceptin (trastuzumab) / Roche
Review, Journal: Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini Review. (Pubmed Central) - Oct 27, 2022
Resistance, however, develops soon. The present report that reviews the investigations that have been carried out by earlier workers for targeting to ErbB1, ErbB2, and both using small molecules and novel peptides that could help/facilitate researchers to design and develop better cancer chemotherapy.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATION CONFERS RESISTANCE TO LENVATINIB IN THYROID CANCER CELLS () - Oct 26, 2022 - Abstract #ATA2022ATA_340;
The results indicate that signal transduction via the EGFR pathway may be involved in the development of lenvatinib resistance in thyroid cancer cells. The inhibition of the EGFR pathway simultaneously by an EGFR inhibitor may have therapeutic potential for overcoming lenvatinib resistance in thyroid cancer.
- || temozolomide / Generic mfg.
Review, Journal: Temozolomide in aggressive pituitary tumours and pituitary carcinomas. (Pubmed Central) - Oct 25, 2022
Treatment options following disease progression after TMZ remain unclear but include a second course of TMZ, immunotherapy and targeted oncological agents such as bevacizumab and lapatinib as well as peptide receptor radionuclide treatment (PRRT). An experienced pituitary multidisciplinary team is essential to all management decisions in patients with APT/PC.
- | lapatinib / Generic mfg.
Journal, IO biomarker: A Novel Oxidative Stress-Related lncRNA Signature That Predicts the Prognosis and Tumor Immune Microenvironment of Breast Cancer. (Pubmed Central) - Oct 25, 2022
Higher macrophage scores were acquired in the high-risk group, of which patients showed more response to conventional chemotherapy drugs, such as AKT inhibitor VIII and Lapatinib, as well as immunotherapy strategies including anti-CD80, TNF SF4, CD276, and NRP1. The prognosis of breast cancer can be independently predicted by the markers, which sheds light on further research of the specific role of lncRNAs which are oxidative stress-related and clinical treatment of breast cancer.
- | lapatinib / Generic mfg.
Journal, BRCA Biomarker: Characterization of glucose metabolism in breast cancer to guide clinical therapy. (Pubmed Central) - Oct 25, 2022
Additionally, the high-risk group was more sensitive to Lapatinib...We identified a novel GRG signature complementing the present understanding of the targeted therapy and immune biomarker in breast cancer. The GRGs may provide fresh insights for individualized management of BRCA patients.